NVIDIA and Eli Lilly and Company announced a joint AI co-innovation lab focused on advancing drug discovery. The companies plan to invest up to $1 billion over five years in talent infrastructure and compute.
Based in the San Francisco Bay Area, the lab will bring together Lilly scientists and NVIDIA AI researchers to work side by side. The infrastructure will use the NVIDIA BioNeMo platform and next generation NVIDIA Vera Rubin architecture to build large scale AI models for biology and chemistry.
The collaboration will first focus on a continuous learning system that connects wet lab experiments with computational modeling. This setup allows data experiments and AI models to inform each other around the clock. The teams will also explore robotics and physical AI to accelerate medicine discovery and manufacturing.
Work at the lab is expected to begin in South San Francisco early this year.
Leave a comment